EGR3 and B-cell chronic lymphocytic leukemia: Therefore, additional inhibition of IL6-JAK-STAT pathway may be a potential option for EGR3-low or U-CLL patients, which facilitate the clearance of residual CLL cells in protective bone marrow microenvironment after ibrutinib treatment.